Abrahim SC, Bansraj D, Edwards R, Thompson R, Rambaran R, Roach A, Warner WA, Chalapathi Rao AV, Unakal C, Haraksingh RR. Genetic screening of FFPE breast cancer biopsies for the
BRCA1-185delAG mutation in Trinidad and Tobago.
Rev Panam Salud Publica 2025;
49:e52. [PMID:
40395657 PMCID:
PMC12091074 DOI:
10.26633/rpsp.2025.52]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2024] [Accepted: 03/24/2025] [Indexed: 05/22/2025] Open
Abstract
Objective
To investigate whether the quality and quantity of genomic DNA harnessed from existing formalin-fixed paraffin-embedded (FFPE) breast cancer biopsy tissue samples in the public health system of Trinidad and Tobago (T&T) were sufficient for downstream genetic testing and to investigate the occurrence of the common breast cancer susceptibility gene 1 (BRCA1) mutation, BRCA1-185delAG, in these samples.
Methods
Genomic DNA was extracted from 67 FFPE samples using a standard protocol (Qiagen). Samples were genotyped using polymerase chain reaction (PCR) and Sanger sequencing.
Results
The genomic DNA was highly fragmented in the 250-500 bp range. The quality and quantity only allowed testing of one variant. This study successfully genotyped 34 of 67 FFPE breast cancer tissue biopsy samples for the BRCA1-185delAG mutation. This mutation was not detected in the 34 samples.
Conclusion
Existing FFPE cancer tissue biopsies in the public health system in T&T are of limited utility for genetic testing. The absence of the BRCA1-185delAG mutation in the limited number of breast cancer samples tested does not preclude its existence in this population. Further investigations are needed to determine the extent of clinically relevant breast cancer-associated mutations in this population.
Collapse